ABSTRACT
Twenty-seven years ago it was described that the rate of decline in glomerular filtration rate (GFR) correlated with clinic blood pressure (BP) in patients with overt diabetic nephropathy [1]. This observation, which was in remarkable contrast to the prevailing concepts, subsequently formed the part of the basis for antihypertensive treatment in patients with diabetic nephropathy, one of the most clinically significant interventions in modern diabetology, documented to preserve GFR [2-5] and reduce mortality [6-8]. However, although these beneficial effects are of immense importance, evaluation of all available studies document that despite antihypertensive treatment a significant proportion of patients still develop end-stage renal disease - “acquiring the goal” has not yet been fully accomplished [9].
